Search clinical trials for: CC-1088

Total 1075 results

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Not yet recruiting

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer
Andarix Pharmaceuticals

Recruiting

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Carcinoma, Small Cell | Neoplasm Recurrence, Local

United States
Axon Neuroscience SE

Completed

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (FUNDAMANT)

Alzheimer's Disease

Austria
Dynavax Technologies Corporation
United States Department of Defense

Active, not recruiting

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Vaccine-Preventable Diseases | Plague | Plague, Pneumonic

United States
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)

Smoking

Japan
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States, Israel, Italy, Spain, United Kingdom
Aravax Pty Ltd

Recruiting

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Immune System Diseases | Peanut Hypersensitivity | Peanut Allergy | Peanut-Induced Anaphylaxis

United States, Australia
Fondazione Don Carlo Gnocchi Onlus

Recruiting

EffectiVenEss of a Rehabilitation Treatment With Nordic Walking in obEse or oveRweight Patients (VENERE)

Cardiovascular Diseases | Overweight and Obesity | Diabete Type 2

Italy
George E. Peoples
PalloV, LLC

Completed

Trial of PalloV-CC in Colon Cancer

Colon Cancer

United States
Ohio State University
Stryker Instruments

Completed

Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy -- Use in Acute Cholecystitis Sub-Study (NIRF-C Acute)

Acute Cholecystitis | Acute Cholangitis

United States
AstraZeneca

Withdrawn

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer. (LARES)

Breast Cancer

China
Celgene

Approved for marketing

Expanded Access for CC-486

Acute Myelogenous Leukemia (AML)

United States
Bristol-Myers Squibb

Recruiting

An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission

Leukemia, Myeloid, Acute

China
Ohio State University
Society of American Gastrointestinal and Endoscopic Surgeons; Stryker Instruments

Completed

Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy (NIRF-C)

Cholecystitis

United States
Celgene

Recruiting

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

United States
Juno Therapeutics, a Subsidiary of Celgene

Active, not recruiting

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Terminated

A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)

Advanced Solid Tumors

Canada, United States, Denmark, Israel, Switzerland
University of Florence

Recruiting

Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients (FLO_CC-486-)

MDS | CMML

Italy
Celgene

Recruiting

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States, Belgium, Australia, Canada, Austria, Germany, Israel, Italy, Japan, Poland, Portugal, Spain, United Kingdom, Argentina, Switzerland
Celgene

Completed

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants

Healthy Volunteers

United States
Philip Morris Products S.A.

Completed

Exploratory THS 2.1 Nicotine Pharmacokinetics and Safety Study

Smoking

United Kingdom
Celgene

Completed

Radiolabeled Study of CC-220 in Healthy Male Subjects

Healthy Volunteer

United States
Celgene

Completed

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States
Kirby Institute
Celgene

Active, not recruiting

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia
Celgene

Completed

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

Canada, United States, Taiwan, France, Spain, Greece, Italy, Singapore, Tunisia
Boehringer Ingelheim

Completed

Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Splash Pharmaceuticals, Inc.

Unknown

Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer

Ovarian Epithelial Cancer

United States
Guangzhou Institute of Respiratory Disease

Recruiting

Analysis of the Reliability and Validity of the Chinese Version of CC-QoL

Chronic Cough

China
Philip Morris Products S.A.

Completed

Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.

Smoking

Poland
University of Toronto

Completed

Dietary Approach to Stop Hypertension With Sodium (Na) Reduction for Chinese Canadians (DASHNa-CC)

Hypertension
Clover Biopharmaceuticals AUS Pty Ltd

Terminated

Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases (COVID-19)

COVID-19

Ukraine
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin

Healthy
Cocrystal Pharma, Inc.
hVIVO Services Limited

Recruiting

Influenza Viral Challenge Study of CC-42344 in Healthy Participants

Influenza A

United Kingdom
Juno Therapeutics, a Subsidiary of Celgene

Active, not recruiting

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lymphoma Non-Hodgkin | Agressive Lymphoma | Diffuse-large B-cell Lymphoma (DLBCL)

United States, Canada
University of Cambridge
Imperial College London

Completed

The Effects of Types of Fruits and Vegetables on Vascular Function (CIRCUS)

Blood Pressure | Vascular Stiffness | Cardiovascular Risk Factor

United Kingdom
Dynavax Technologies Corporation

Completed

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

Hepatitis B

United States
Celgene

Completed

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Neoplasm Metastasis | Prostate Cancer | Chronic Lymphocytic Leukemia | Glioblastoma Multiforme | Squamous Cell Carcinoma of Head and Neck | Ewing's Osteosarcoma

United States, Spain, France, Germany
Newave Pharmaceutical Inc

Active, not recruiting

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Refractory Acute Lymphoblastic Leukemia | Relapse | CMML | Relapsed Adult AML | AML/MDS | Relapse Leukemia

United States, Spain
Dynavax Technologies Corporation

Completed

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Herpes Zoster | Vaccine-Preventable Diseases | Shingles

Australia
NuvOx LLC
The Alfred

Completed

The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma (GBM)

Glioblastoma Multiforme

Australia
Yale University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Withdrawn

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Acute Myeloid Leukemia

United States
Celgene

Active, not recruiting

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Neoplasms | Hematologic Malignancies | Hematologic Neoplasm

United Kingdom, United States
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food

Healthy
InFlectis BioScience
Assistance Publique Hopitaux De Marseille; Qualissima; Eurofins Optimed; Stragen...

Completed

A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088

Healthy Volunteers

France
AbbVie
Roche-Genentech

Active, not recruiting

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

Acute Myeloid Leukemia (AML)

United States, Australia, Canada, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Translational Research in Oncology
Celgene

Terminated

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

Epithelial Ovarian Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Diffuse Large B-Cell Lymphoma | Multiple Myeloma | Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Glioblastoma Multiforme | Neuroendocrine Tumors of Non-Pancreatic Origin | Hormone Receptor-Positive Breast Cancer

United States, Spain, United Kingdom, France
Philip Morris Products S.A.

Completed

Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting

Smoking

Japan

3

Subscribe